Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy

• 485 · PDF ML-016: A silicon “plateloid”-based phenotype targeting platform for lung and liver malignancies Qingxin Mu, Lorenzo Pradella, Brian Sapp, Mauro Ferrari
• 7144 7144 A general method to overcome the binding site barrier in antibody-based therapeutics Yuanzheng Li, Shili Yao, Peng Guo
• 7145 7145 A spatial PK/PD framework predicts ADC response in solid tumors by integrating drug delivery, target engagement, and microenvironmental readiness Corinne Ramos, Martha Baydoun, Sandra Delebecq, Amandine Gerstenberg
• 7146 · PDF Targeting tumor macrophage TGF-beta signaling overcomes immunotherapy resistance in hepatocellular carcinoma Hui Yue, Yan Liu, Han Wang, Yalin Tu, Yaxian Wang, Siyuan Huang, Haoran Wu, Xiaohang Long, Carol Tong, Alfred Sze-Lok Cheng
• 7147 · PDF CAR T-Cell therapy efficacy evaluation inTumorGraft3D tri-culture platform with reconstructed tumor microenvironment Stefano Cairo, Fu-Ju Chou, Sumanun Suwunnakorn, Annamaria Rapisarda, Marianna Zipeto, Michael Ritchie, Markus Hippich, Daniel Ciznadija, Veena Jagannathan, Brandon Walling, Mara Gilardi, Haoting Hsu, BanuPriya Sridharan
• 7148 7148 Stress adaptation defines therapeutic response to CDK4/6 inhibitors in sarcoma Jinfen Xiao, Emily Ko, Ashley Smith, Roberta Piras, Annaliese Fowler, Kristin Ishaya, Jlenia Guarnerio
• 7150 · PDF ICA-1S targets protein kinase C-iota to inhibit the WNT/beta-catenin signaling in hepatocellular carcinoma Abigail Oluwafisayo Olatunji, Nuzhat Nowshin Oishee, Abiral Hasib Shourav, Grazielly Teodoro, Mildred Acevedo-Duncan
• 7151 7151 Targeted inhibition of atypical PKC isoforms PKC-ι and PKC-ζ by ICA-1S and ζ-Stat suppresses oncogenic signaling and cytokine-mediated bone metastasis in prostate cancer Grazielly Teodoro, Wishrawana Sarathi Ratnayake, Luke Lajmi, Sloan Breedy, Aaron Todman, Shreejana Rimal, Mildred Acevedo-Duncan
• 7152 · PDF ICA-1S targets PKC-ι and Cx43 to inhibit glioblastoma multiforme progression Grazielly Teodoro, Shreejana Rimal, Wishrawana Sarathi Ratnayake, Gaurab Raj Khanal, mildred acevedo-duncan
• 7153 7153 Selective atypical protein kinase C inhibitor reduces proliferation and promotes apoptosis in malignant endometrial cancer cells Gaurab Raj Khanal, Shreejana Rimal, Grazielly Teodoro, Mildred Acevedo-Duncan
• 7154 · PDF The role of TNIK and MINK1 in TNBC tumorigenesis and invasion Caroline McCauley, Bruce Bunnell
• 7155 7155 Therapeutic potential of a selective protein kinase Ciota inhibitor, in suppressing PI3K/AKT driven pancreatic ductal adenocarcinoma proliferation Shreejana Rimal, Grazielly Teodoro, Gaurab Raj Khanal, Abigail Oluwafisayo Olatunji, Abiral Hasib Shourav, Mildred Acevedo-Duncan
• 7156 · PDF Inhibition in the proliferation of pediatric glioblastoma facilitated with atypical protein kinase c inhibitors Shreejana Rimal, Grazielly Teodoro, Gaurab Raj Khanal, Mildred Acevedo-Duncan
• 7157 · PDF Programmable RNA-triggered cancer cell elimination using CRISPR-Cas12a2 Jared Thompson, Paul Scholz, Kadin Crosby, Nathan Krah, Grant Schlauderaff, Alivia Jolley, Emily Wilson, Xiaoyang Zhang, Ryan Jackson, Chase Beisel, Yang Liu
• 7158 · PDF Human sialidase-armed anti-B7-H3 antibody that enhances innate and adaptive antitumor immune responses Wayne Gatlin, Jen-Kuan Chang, Lizhi Cao, Hui Xu, Hrishikesh Metha, Maryann Timins, Mark Yang, Jim Broderick, Yanling Wang, Wilbert Tam, Grace Chung, Chunlei Ge, Lixin Feng, Li Peng
• 7159 · PDF Antitumor activity of Avaren-Fc, a novel high-mannose-glycan-targeting immunotherapy, in ovarian cancer Katarina Mayer, Noel Verjan-Garcia, Nobuyuki Matoba
• 7160 · PDF NEK2 drives pathogenesis, drug resistance, and LMP1 expression in EBV-positive non-Hodgkin lymphoma Maria C. White, Philip T. Lange, Blossom A. Damania
• 7161 · PDF A novel StarLinker TM -based, CLDN18.2/PD-L1 bispecific dual-payload ADC (CAN017) overcomes tumor heterogeneity Pengqi Xu, Shaoshan Wang, Sanlong Wang, Ya Luo, Yili Yang, Wanping Geng, Weihao Li, Liying Li, Qin Pan, Xiangdong Qu, Henry N. Yu
• 7162 · PDF CD180-targeting ADCs with a topoisomerase I inhibitor payload achieve strong efficacy in AML tumors Garima Kaushik, Marina Bell, Bandana Vishwakarama, Abdul Mondal, Maxwell Hilbert, Arnab Mukharjee, Michael Ritchie, Kakajan Komurov
• 7164 7164 Preclinical characterization of TRO-01, a novel CLDN18.2-targeting ADC, with potent anti-tumor efficacy and favorable PK and safety Young Hun Lee, Jeongho Kim, Hyun Ju Lee, Sunhwa Lee, Dong Hoon Seo, Myoungki Baek, Sung Ho Woo
• 7165 · PDF The role of NEK2 and AURKB on triple-negative breast cancer progression Elliott Rodriguez-Lopez, Alexandra Aquino-Acevedo, Joel Orengo-Orengo, Gretchen Albarran-Acosta, Katiushka Berrocales, Harold Saavedra

在会议检索中浏览本分会场